



**ASX Announcement | 9 September 2020**  
**Noxopharm Limited (ASX:NOX)**

## **Noxopharm Appoints New Chair**

**Sydney, 9 September 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX)** announces the appointment of Mr Fred Bart as Non-Executive Chair, allowing Executive Chair and CEO, Dr Graham Kelly, to focus on the CEO role.

Dr Kelly assumed both roles with the departure in mid-2019 of the previous CEO. While this was always regarded as a temporary measure, recent expansion of the Company's R&D and commercial activities has brought to a head the need to split the roles. This will allow Dr Kelly to focus on running the Company's business in conjunction with his senior executive team of Dr Gisela Mautner (CMO) and Jeanette Bell (COO).

**Dr Kelly said,** 'The appointment of Mr Bart to the Noxopharm Board a few months ago brought an injection of business skills which the Board was keen to see exploited more fully by his appointment as Non-Executive Chair. At heart, Noxopharm is driven by a blend of science and entrepreneurship. But with exponential growth comes the need for hard-nosed business skills, which Fred brings. I look forward to working with Fred to deliver on what we both see as a major commercial opportunity'.

**Mr Fred Bart said,** 'I am honoured to take on this role and look forward to working closely with the board and management in the exciting next chapter of the company's development.'

Dr Kelly remains as CEO and on the Noxopharm Board as Managing Director.

*Graham Kelly, CEO, has approved the release of this document to the market on behalf of the Board of Directors.*

**-ENDS-**

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

The Company's second pipeline candidate is a novel metabotropic glutamate receptor inhibitor for the treatment of brain cancers.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).



To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor & Corporate enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media Enquiries**

Julia Maguire

The Capital Network

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

T: + 61 2 8999 3699

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.